





Association of Breast Surgery Conference & AGM 21st and 22nd May 2012, Bournemouth International Centre



Welcome from the President



Welcome to Bournemouth - the Association's first visit to this popular coastal resort. Mark Sibbering has once again worked very hard to put together a really lively and stimulating two days, including topics which you prioritised following last year's Manchester meeting. The ABS is moving from strength to strength, with a membership which has recently topped 1,000. This year we are hoping for a record number of delegates, and have judged the highest number of abstracts ever submitted. I would like to encourage members to attend our AGM on Monday, which will include some important membership and financial issues. As always, we rely heavily on corporate subsidy to give you value for money, and I would be very grateful if you could spare a few minutes to visit their stands.

Once again, we are very fortunate to host some major international opinion leaders during the programme. Professor Lori Pierce will discuss the practice-changing Z0011 trial, and will review the evidence for breast conservation for BRCA patients in her BJS Lecture. The world-renowned cancer epidemiologist Professor Peter Boyle will give us an update on risk factors and over-diagnosis, and Professor Maurizio Nava will cover the increasingly contentious topic of radiotherapy after implant-based reconstruction in his EJSO Lecture. And finally, we look forward to some lively and thought-provoking contributions from Professor Mike Dixon. By popular demand, the programme includes parallel sessions for Breast Care Nurses, covering patient support, advanced disease and a debate on the future role of the specialist nurse, and the Mammary Fold, who will be hosting a symposium on oncoplastic topics.

As always, the meeting focuses on issues which are directly relevant to your clinical practice, in those areas where decision-making is often most challenging. This year we will be debating a number of hot topics, including the management of the positive sentinel node, some of the difficult decisions faced by recently diagnosed young patients and their MDTs, and current concerns about the over-diagnosis and over-treatment of early lesions. This topic links through to our regular Breast Cancer Audit session, where Professor Julietta Patnick will give an update on the important independent review of the NHS Breast Screening Programme recently commissioned by Professor Mike Richards, followed by Dr Gill Lawrence who is to be congratulated for presenting the annual breast audit data for longer than I can remember.

Training is our lifeblood, and the future of our specialty lies in the hands of the next generation. Important opinions about the future configuration of breast surgery will be presented in a session which includes contributions by breast and plastic surgeonsculminating in a debate on the future of oncoplastic breast surgery which promises to be lively! Following the success of last year's popular oncoplastic surgery symposium, the meeting will conclude with updates, concerns and a stimulating interactive discussion highlighting some difficult oncoplastic dilemmas.

Finally, Bournemouth enjoys one of the most pleasant climates in the UK, with above average temperatures and long sunny days. I do hope you will find some time to wind down and take a relaxing stroll along one of the South's most beautiful beaches.

Dick Rainsbury

President of the ABS



Programme

21st and 22nd May 2012, Bournemouth International Centre

Monday 21st May 2012 - At a glance

	Tregonwell Hall	Purbeck Lounge	Bayview Suite
09:00 - 10:30	Session 1 BJS Prize Papers	Session 2 Patient Information and Support	Session 3 Submitted Papers
10:30 - 11:00	Tea & Coffee Break (Purbeck	Hall)	
11:00 - 12:30	Session 4 Management of the positive sentinel node		
12.30 -14:00	Lunch (Purbeck Hall)		
12:30 -13:15	ABS AGM (open to ABS Members only)		
13:15 -13:45		ABS Affiliate and Nurse Unit Members' Business Meeting	
14:00 -14:30	Session 5 British Journal of Surgery Lecture		
14:30 -16:00	Session 6 Breast Cancer in Young Women	Session 7 Mammary Fold Session	Session 8 Techniques and Technologies Workshop
16:00 - 16:30	Tea & Coffee Break (Purbeck	Hall)	
16:30 -18:00	Session 9 Surgical Practice: Guidelines and Audit	Session 10 Caring for patients with secondary breast cancer	Session 11 Submitted papers
18:00 - 18:45		Mammary Fold AGM	
18:00 -19:15	Poster Viewing and Drinks R	eception (Purbeck Hall)	

09:00 Tregonwell Hall Welcome from Mr Dick Rainsbury and Mr Mark Sibbering

Tregonwell Hall 09:05 to 10:30

Session 1	BJS Prize Papers Chairs: Mr Dick Rainsbury & Mr Martin Lee
09:05 to 09:15	1.20-year analysis of the Nottingham EPSII – A randomised trial of primary tamoxifen versus initial mastectomy plus adjuvant tamoxifen in older women with oestrogen receptor rich early operable invasive breast carcinoma SJ Johnston, University of Nottingham
09:15 to 09:25	2. Understanding decision-making for reconstructive breast surgery: A qualitative study Shelley Potter, University of Bristol
09:25 to 09:35	3. Should the axilla be managed less aggressively in selected node-positive breast cancer patients? Georgina Walker, Nottingham University Hospitals
09:35 to 09:45	4. Multiple step-section frozen section sentinel lymph node biopsy - a highly reliable intra-operative test: A review of 717 patients Jeffrey Lim, Gloucestershire Hospitals NHS Trust
09:45 to 09:55	5. Systematic evaluation of decision-making in multidisciplinary breast cancer teams: A Prospective, cross-sectional study Sonal Arora, Imperial College, London
09:55 to 10.05	6. Validation of a technique using microbubbles and contrast enhanced ultrasound to identify and biopsy sentinel lymph nodes in pre-operative breast cancer patients Karina Cox, Maidstone and Tunbridge Wells Breast Clinic
10.05 to 10:15	7. Intra-operative Sentinel Lymph Node Assessment- How many patients will avoid a second operation? Jonathan Horsnell, Cheltenham General Hospital
10:15 to 10:25	8. Clinical outcomes of surgically treated octogenarians with breast cancers over a 5 years period Melissa Ley-Hui Tan, Russells Hall Hospital, Dudley

09:00 to 10:30 Purbeck Lounge

Session 2	Patient Information and Support Chair: Mrs Sue Holcombe
09:00 to 09:25	End of treatment assessments and treatment summaries Miss Amanda Shewbridge, Guy's Hospital, London
09:25 to 09:50	Intra-operative analysis: How do we support the patient? Dr Carmel Sheppard, Queen Alexandra Hospital, Portsmouth
09:50 to 10:05	Walking in my shoes - WIMS Explained Dr Louise Clark, Royal Liverpool University Hospital
10:05 to 10:15	Patient Experience of WIMS
10:15 to 10:30	Discussion

09:00 to 10:30 Bayview Suite

Session 3	Submitted Papers Chairs: Mr Stewart Nicholson & Mr Neil Rothnie
09:00 to 09:08	9. Over 70- What will happen to me? Will I die from my breast cancer? Caroline Mortimer, Anglia Breast Cancer Network
09:08 to 09:16	10. Trastuzumab (Herceptin®) induced cardiotoxicity in the elderly population: do we need to re-assess prescribing practices? David Naumann, Sandwell and West Birmingham Hospitals
09:16 to 09:24	11. The effect of a 'false positive' recall on intention to re-attend for screening mammography Emma de Sousa, North Manchester General Hospital
09:24 to 09:32	12. The role of triple assessment in benign breast disease Thomas Fysh, Royal Devon and Exeter NHS Foundation Trust
09:32 to 09:40	13. Is mode of presentation (screening or symptomatic) a distinguishing factor in the pathology of B3 core biopsies? Gael M MacLean, Royal Berkshire Hospital, Reading
09:40 to 09:48	14. Granulomatous mastitis - A novel method of treatment <i>Kailas Munot, York Teaching Hospital NHS Foundation Trust</i>
09:48 to 09:56	15. Does the use of 'KliniTray' to orientate wide local excisions in breast cancer improve the rate of clear margins and reduce re-excision rates? Jessica Phillips, Chesterfield Royal Hospital
09:56 to 10:04	16. Comparison of Metasin versus Genesearch© (Veridex) in Intraoperative Analysis (IOA) of Sentinel Lymph Nodes (SLN) in Breast Cancer (BC). Tracey Simoes, Queen Alexandra Hospital, Portsmouth
10:04 to 10:12	17. Skin-reducing mastectomy (SRM) with immediate implant based reconstruction is oncologically safe Caroline Richardson, The Royal Wolverhampton Hospitals NHS Trust
10:12 to 10:20	18. Radiotherapy: Patient Reported Outcomes following Post Mastectomy Breast Reconstruction Aasma Al-Allak, The Great Western Hospital, Swindon

11:00 to 12:30 Tregonwell Hall

Session 4	Management of the positive sentinel node Chair: Mr Kieran Horgan
11:00 to 11:20	Are the ACOSOG Z0011 trial results transferable outside North America? Prof Lori Pierce, University of Michigan Medical School, USA
11:20 to 11:30	UK radiotherapy protocols Prof David Dodwell, Leeds University Hospitals
11:30 to 11:45	Current management of the axilla in the UK: Audit Data Dr Gill Lawrence, WMCIU & Mr Neil Rothnie, Southend University Hospital
11:45 to 12:05	Do we need another trial or a change in practice? Prof Michael Dixon, Western General Hospital, Edinburgh
12:05 to 12:30	Discussion to produce an ABS Consensus Statement

14:00 to 14:30 Tregonwell Hall

Session 5	British Journal of Surgery Lecture Chair: Mr Dick Rainsbury
14:00 to 14:30	Breast conserving therapy in BRCA 1/2 gene mutation carriers Prof Lori Pierce, University of Michigan Medical School, USA

14:30 to 16:00 Tregonwell Hall

Session 6	Breast Cancer in Young Women Chair: Miss Julie Doughty
14:30 to 14:45	Breast cancer epidemiology and risk factors in young women Prof Peter Boyle, International Prevention Research Institute, Lyon, France
14:45 to 15:05	Pathology and biology of breast cancer in young women Prof Louise Jones, Barts & the London NHS Trust
15:05 to 15:25	Breast cancer treatment issues specific to young women: Premature menopause, fertility issues and diagnosis in pregnancy Dr Alison Jones, University College Hospitals, London
15:25 to 15:45	Breast reconstruction: Why should we delay? Prof Michael Kerin, University College Hospital, Galway
15:45 to 16:00	Discussion

14:30 to 16:00 Purbeck Lounge

Session 7	Mammary Fold Session Chair: Ms Sue Down
14:30 to 14:50	Oncoplastic Breast Surgery in Italy Prof Maurizio Nava, National Institute for Cancer, Milan, Italy
14:50 to 15:10	Breast reduction surgery: Tips and markings Mr Douglas Macmillan, Nottingham Breast Institute
15:10 to 16:00	Interactive case discussions Panel: Prof Maurizio Nava, Mrs Katy Hogben, Mr Douglas Macmillan, Prof David Dodwell

14:30 to 16:00 Bayview Suite

Session 8	Techniques and Technologies Workshop (Sponsored Session) Chair: Mr Lee Martin
14:30 to 14:40	Fat transfer using multi-layered filtration Puregraft Technology Ms Jacqueline Lewis, Charing Cross Hospital, London
14:40 to 14:50	Stem and regenerative cell supplemented fat transfer using Celution Mr Nader Khonji, Singleton Hospital, Swansea
14:50 to 15:10	New PICO single-use negative pressure system: Reducing complications and improving the aesthetic outcome in breast surgery Mr John Timmons, Clinical Project Manager, Smith & Nephew
15:10 to 15:30	Advances in SLNB imaging Mr Neil Whalley, Avail Medical
15:30 to 16:00	Workshop demonstrations

This session is sponsored by Avail Medical, Cytori Gmbh and Smith & Nephew

16:30 to 18:00 Tregonwell Hall

Session 9	Surgical Practice: Guidelines and Audit Chair: Mr Stewart Nicholson
16:30 to 16:40	New oncoplastic guidelines <i>Mr Dick Rainsbury, Royal Hampshire County Hospital, Winchester</i>
16:40 to 16:50	Lipomodelling guidelines <i>Mr Lee Martin, Aintree University Hospital, Liverpool</i>
16:50 to 17:00	Discussion

continued....

Session 9	Surgical Practice: Guidelines and Audit continued
17:00 to 17:15	Sloane Project Update Prof Alastair Thompson, Ninewells Hospital, Dundee
17:15 to 17:30	Recurrent and metastatic breast cancer data collection pilot project Mr Martin Lee, NHS Warwickshire
17:30 to 17:45	ABS audits update Dr Gill Lawrence, West Midlands Cancer Intelligence Unit
17:45 to 18:00	Discussion

16:30 to 18:00 Purbeck Lounge

Session 10	Caring for patients with secondary breast cancer Chair: Dr Carmel Sheppard
16:30 to 17:00	Addressing the unmet needs in women with metastatic breast cancer Miss Liz Reed, Breast Cancer Care
17:00 to 17:30	The role of the Secondary Breast Cancer Clinical Nurse Specialist Mrs Melissa Warren, Royal Marsden Hospital, Sutton
17:30 to 18:00	Discussion

16:30 to 18:00 Bayview Suite

Session 11	Submitted Papers Chair: Mr Mark Sibbering and Mr Kieran Horgan
16:30 to 16:38	19. Breast oncological surgery and local recurrence in a Prospective study of Outcome of Sporadic versus Hereditary breast cancer (POSH) Ramsey Cutress, University Of Southampton
16:38 to 16:46	20. Family History Clinic: Delivering an efficient cost effective service Lynne Horton, Hull and East Yorkshire Breast Care Unit
16:46 to 16:54	21. Important increase in breast cancer incidence in South Asian women Anne Stotter, University Hospitals of Leicester
16:54 to 17:02	22. Clinical Outcome and Patient Satisfaction Following Implementation of Day Case/23 Hour Breast Surgery Pathway at a University Teaching Hospital Ilyas Khattak, The Royal Liverpool University Teaching Hospital
17:02 to 17:10	23. Predict: A population based validation of a prognostic model for early breast cancer that includes HER2 Gordon Wishart, Anglia Ruskin University
17:10 to 17:18	24. A retrospective audit of outcomes for immediate breast reconstruction Jyotirmoy Roy, Leeds General Infirmary
17:18 to 17:26	25. A Multi centre prospective longitudinal study evaluating the integration of Patient Reported Outcomes (PROMS) with key clinical outcomes after immediate Latissimus dorsi (LD) breast reconstruction and adjuvant treatment Zoë Winters, Bristol Royal Infirmary
17:26 to 17:34	26. Adipose derived regenerative stem cells in breast surgery – current applications and future perspectives James Harvey, University Hospital of North Tees, Stockton-on-Tees
17:34 to 17:42	27. Fluorescence mapping with indocyanine green (ICG) for sentinel lymph node detection in early breast cancer-results of the ICG-10 study John Benson, Cambridge Breast Unit
17:42 to 17:50	28. Recent experience of neoadjuvant chemotherapy for breast cancer at a UK teaching hospital Tim Rattay, University Hospitals of Leicester

Tuesday 22nd May 2012

Tuesday 22nd May 2012 - At a glance

	Tregonwell Hall	Purbeck Lounge
09:00- 11:00	Session 12 Oncoplastic Surgical Training	Session 13 Breast Cancer Audit
11:00- 11:30	Tea & Coffee Break (Purbeck Hall)	
11:30 - 13:00	Session 14 Overdiagnosis and Overtreatment	Session 15 Poster Presentation Session
13.00 -14:00	Lunch (Purbeck Hall)	
14:00 -14:30	Session 16 EJSO Lecture	Session 17 The Changing Role of the Breast Care Nurse
14:30 -16:30	Session 18 Oncoplastic Breast Surgery	
16:30	Close of meeting	

09:00 to 11:00 Tregonwell Hall

Session 12	Oncoplastic Surgical Training Chair: Miss Fiona MacNeill
09:00 to 09:15	MS in Oncoplastic Breast Surgery update Prof Jerome Pereira, James Paget University Hospital, Great Yarmouth
09:15 to 09:30	10 years of the Oncoplastic Fellowships Ms Anne Tansley, Royal Liverpool University Hospital
09:30 to 09:40	Specialist breast surgical training – is it dead? Miss Fiona MacNeill, Royal Marsden Hospital, London
09:40 to 09:50	New oncoplastic breast surgery curriculum development: Plastic Surgery Ms Vivien Lees, University Hospitals of South Manchester
09:50 to 10:00	Discussion
10:00 to 11:00	ABS & BAPRAS Debate: Is there a future for a unified subspecialty in Oncoplastic Breast Surgery?
	For: Mr Dick Rainsbury, Royal Hampshire County Hospital, Winchester Mr Douglas MacMillan, Nottingham Breast Institute
	Against: Mr John Black, Past President of the Royal College of Surgeons of England Ms Elaine Sassoon, Norfolk & Norwich University Hospital

09:00 to 11:00 Purbeck Lounge

Session 13	Breast Cancer Audit Chair: Mr Neil Rothnie
09:00 to 09:15	Update on the independent review of the NHS Breast Screening Programme Prof Julietta Patnick, Director, NHS Cancer Screening Programmes
09:15 to 11:00	Analysis of breast cancer audit data Dr Gill Lawrence, West Midlands Cancer Intelligence Unit External commentator: Prof Michael Dixon, Western General Hospital, Edinburgh

Tuesday 22nd May 2012

11:30 to 13:00 Tregonwell Hall

Session 14	Overdiagnosis and Overtreatment Chair: Mr Mark Sibbering
11:30 to 11:45	Breast Screening: What is the magnitude of overdiagnosis? Prof Peter Boyle, International Prevention Research Institute, Lyon, France
11:45 to 12:00	Are we carrying out too many mastectomies? Prof Michael Dixon, Western General Hospital, Edinburgh
12:00 to 12:15	Should we be offering contralateral mastectomy? Miss Fiona MacNeill, Royal Marsden Hospital, London
12:15 to 12:30	How should we manage LCIS? Mrs Katy Hogben, Charing Cross Hospital, London
12:30 to 13:00	Discussion

11:30 to 13:00 Purbeck Lounge

Session 15	Poster Presentation Session Chairs: Mr Lee Martin and Prof Alastair Thompson
11:30 to 13:00	Oral presentation of the 10 best posters

14:00 to 14:30 Tregonwell Hall

Session 16	EJSO Lecture Chair: Miss Fiona MacNeill
14:00 to 14:30	Radiotherapy and implant based breast reconstruction: Are they compatible? Prof Maurizio Nava, National Cancer Institute, Milan, Italy

14:00 to 15:15 Purbeck Lounge

Session 17	The Changing Role of the Breast Care Nurse Chair: Ms Amanda Shewbridge	
14:00 to 14:15	Background to the debate Ms Amanda Shewbridge, Guy's Hospital, London	
14:15 to 15:15	Debate: The traditional BCN role and the NP role are different, and the two roles should not be combined	
	For: Ms Rachel Owers, Gloucestershire NHS Foundation Trust Ms Julia Lambert, Royal Marsden Hospital, London	
	Against: Mrs Joanna Rowley, Addenbrookes Hospital, Cambridge Mrs Veronica Rogers, Royal Derby Hospital	

Tuesday 22nd May 2012

14:30 to 16:30 **Tregonwell Hall**

Session 18	Oncoplastic Breast Surgery Chair: Mr Dick Rainsbury
14:30 to 14:45	Goldilocks Mastectomy Dr Heather Richardson, Piedmont Hospital, Atlanta, USA
14:45 to 15:00	Lipomodelling <i>Mr Fazel Fatah, City Hospital, Birmingham</i>
15:00 to 15:15	Bilateral therapeutic mammoplasty Mr Douglas Macmillan, Nottingham Breast Institute
15:15 to 15:30	Are oncoplastic techniques putting breast cancer patients at increased risk of recurrence? Miss Julie Doughty, Western Infirmary, Glasgow
15:30 to 16:30	Oncoplastic video case discussions Panel: Prof Michael Dixon Mr Douglas MacMillan Mr Fazel Fatah Prof Maurizio Nava

16:30	Close of Meeting
-------	------------------

JRGEON'S HOICE

Sure & fast lymph node localisation. Guaranteed.



Efficient and easy to use

Plug & Play (no initial calibration)

Best in class sensitivity (CSI Crystal + Pm Tube)

Best in class shielding integrated collimator The electronic control unit is designed for the operating theatre environment. The small, light-weight electronic control unit has an adjustable audible signal for guiding the surgeon's hand and a highly visible digital display of actual probe activity readings even in low ambient light conditions.

Gamma-Sup's intrinsic robustness provides unbeatable longevity and hassle-free long term use. Wear-and-tear and recalibration issues will be a thing of the past.



Unit 1A The Cottage 100 Royston Road Byfleet, Surrey, KT14 7NY E info@daax.co.uk

T 0870 979 9110 F 0870 979 9911

www.daax.co.uk

International Guest Speakers

Prof Peter Boyle



Prof Boyle's appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on from his tenure as Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon. From 1991 - 2004 he was Director of the Division of Epidemiology and Biostatistics at the Institute of Oncology in Milan, Italy. Prior to this he held a number of successive appointments with Glasgow University Department of Medicine, the West of Scotland Cancer Surveillance Unit, Harvard School of Public Health and the International Agency for Research on Cancer (IARC/WHO).

Prof Boyle is also currently Honorary Professor of Cancer Prevention and Control at Oxford University and Dundee University and Visiting Professor at Glasgow University.

Prof Boyle's research interests lie mainly in disease prevention and translational research in its broadest meaning, covering the spectrum from translating cutting-edge scientific discovery into new approaches to cancer treatment, to translating information about cancer risk factors into changes in population behaviour. He led the EUROCAN+PLUS project which developed priorities for coordination of cancer research in Europe. He is the author of more than 500 scientific publications.

Prof Boyle has previously been Director of the World Health Organisation Collaborating Centre for Chronic Disease Epidemiology and a Member of the European Cancer Advisory Board.

Prof Maurizio Nava



Prof Nava is a specialist in Plastic and Reconstructive Surgery, General Surgery and Oncology. He is the chief of the Plastic Surgery Department at the Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori in Milan.

His other positions include:

- Chairman at Scuola di Oncologia Chirurgica Ricostruttiva from 1999
- Scientific consultant for CNR (Research National Council) project in "Associated Treatments" (1978 – 1985)
- Medical Officer in charge of monitoring the International Cooperative Trials carried out by the Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma WHO staff (1992 – 1997)
- Scientific Committee Member at Italian School Of Senology
- · Council member of the Italian society of senology
- Referee of Italian E.C.M.
- Associate professor at plastic surgery specialization schools of the Milan, Genoa and Pavia Universities.
- Author of over 200 papers on cancer and reconstructive surgery and on breast aesthetic surgery

Prof Lori Pierce



Prof Pierce received her medical degree from Duke University in 1985 and completed residency in Radiation Oncology at the University of Pennsylvania in 1989. Prof Pierce was a senior investigator in the Radiation Oncology Branch at the National Cancer Institute (NCI) and joined the Department of Radiation Oncology at University of Michigan in 1992. She is currently Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs. In 2010 she was chosen as an inaugural member of the Scientific Advisory Board of the Susan G. Komen for the Cure Foundation and was elected to the ASCO Board of Directors.

She has published more than 100 papers and book chapters on aspects of radiotherapy in the treatment of breast cancer, and her work has been funded by the NCI, Department of Defense Funds for Breast Cancer Research, and private industry.

Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis upon contemporary radiotherapy treatment planning techniques, the use of radiation in women with breast cancer and a breast cancer susceptibility gene, and potential radiosensitization with PARP inhibitor drugs.

Honors awarded to Prof Pierce have included travel grants from the American Society of Therapeutic Radiology and Oncology and the European Society of Therapeutic Radiology and Oncology, teaching awards, the AMA Women Physician Mentor Award, the Sara Goddard Power Award, Susan G. Komen for the Cure Scholar, and yearly listings in "America's Top Doctors", "Who's Who in Medical Sciences Education" and "Best Doctors in America".

International Guest Speakers

Dr Heather Richardson



Dr. Richardson completed a Bachelor of Science degree in Biology at Wake Forest University in Winston-Salem, North Carolina. She earned her medical degree from the Medical College of Georgia, receiving the CIBA-Geneva Award for outstanding community service in 1998. Dr. Richardson then completed her residency in general surgery at Emory University in Atlanta, Georgia. Dr. Richardson is board certified and is a member of the American College of Surgeons, as well as the American Society of Breast Surgeons.


Dr. Richardson presently serves on the Genetics Steering committee, the Cancer Protocols committee and the Community Outreach committee at Piedmont Hospital and actively participates in the training of Emory University residents in special breast procedures. She is certified in Breast ultrasound and has certification for ultrasound instruction.

Diary Date

patient journey in our podcast at:

www.sysmex-lifescience.com/Penny

ABS Conference & AGM 2013 21st - 22nd May 2013, Manchester Central



Trade Exhibition

The exhibition will be held in the Purbeck Hall and will be open at the following times:

Monday 21st May 2012: 07:45 to 19:15 Tuesday 22nd May 2012: 09:00 to 14:00

The exhibition will contain the following stands:

Adiposet Ltd

Adiposet Ltd medical logistics company facilitating storage and return of autologous adipose tissue for lipomodelling.

Allergan

Allergan is a multi-specialty health care company established more than 60 years ago. Our portfolio includes pharmaceuticals, biologics and medical devices. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, medical aesthetics, breast aesthetics and obesity intervention. Allergan is proud to celebrate more than 60 years of medical advances and are proud to help millions of patients see more clearly, move more freely and express themselves more fully.

Avail Medical

Avail Medical continue to source the latest technology for Breast Surgery and diagnostics with the release of the unique Node Viewer, a wireless hand held Gamma Camera which gives real time identification of lymph nodes, coupled with the new wireless Node Seeker, the new light weight gamma probe, both powered from the same touch screen, windows based control unit. We are pleased to introduce the Flash Biopsy device, a completely disposable core biopsy system that can take up to 15 samples from a single insertion with no capital investment required.


Bard Ltd

Biopsy guns and needles.

Strattice™ Reconstructive Tissue Matrix



The next generation of soft-tissue repair for breast reconstruction postmastectomy



Now that's **Zio**Logical.

LifeCell™ is a pioneer and leader in regenerative medicine for good reason. Demonstrated to support tissue regeneration, 1,2,3,4,5 Strattice™ Tissue Matrix rapidly revascularizes¹ and minimizes adhesions to the implant.² In addition, Strattice™ Tissue Matrix is remodeled and transitioned into host tissue. Studies have shown that others may be resorbed over time, or reside in-situ inertly.3.4 Furthermore, studies have also shown that other matrices may become chronically inflamed and chronic inflammation can have clinically negative effects.⁵ With all these things considered, maybe that's why most surgeons use LifeCell™ Tissue Matrices. Now that's biological.^{1,3,4,5}

To find out more, please visit our stand!

- nodel. Regen Med. 2009; 4(2):185-195
- Connor J, et al. Retention of structural and biochemical integrity in a biologic mesh supports tissue remodeling in a primate abdominal wall model. Regen Med. 2.
 Burns N et al. Non-cross-linked porcine acellular dermal matrices for abdominal wall reconstruction. Plast Reconstructions Turg. 2010;125(1):167-176
 Al Happer JR, et al. A novel regenerative tissue matrix (RTM) technology for connective tissue reconstruction. Wounds. 2007;19(6):163-168.
 Xu H, et al. Host response to human acellular dermal matrix transplantation in a primate model of abdominal wall repair. Tissue Eng. Part A. 2008;14(12):2009.
- 5. Sandor M, et al. Host response to implanted porcine-derived biologic materials in a primate model of abdominal wall repair. Tissue Eng. Part A. 2008 Dec;14(12):2021-2031.



BCCOM & Sloane Project

The Breast Cancer Clinical Outcome Measures (BCCOM) Project is the online audit of symptomatic breast cancers. The Sloane Project is a UK prospective audit of screen-detected non-invasive carcinomas and atypical hyperplasias of the breast.

Blackwell Exhibitions

Book retailer.

Breakthrough Breast Cancer

Breakthrough Breast Cancer is committed to campaigning to change lives and shape futures by securing improvements in breast cancer prevention, diagnosis, treatment and services for everyone affected by breast cancer. We are determined to create a future free from the fear of breast cancer.

Breast Cancer Care

Breast Cancer Care is here for anyone affected by breast cancer. We bring people together, provide information and support, and campaign for improved standards of care. We use our understanding of people's experience of breast cancer and our clinical expertise in everything we do. Find out more at www.breastcancercare.org.uk

Carefix

Carefix offer a range of post-surgical and mastectomy bras, which are designed for the weeks immediately following breast surgery, when the skin is still tender and sensitive. The seamless design and soft fabric used offer the perfect balance between compression and comfort. All materials used are latex free as well as Oeko-Tex certified.

Carl Zeiss Ltd

Intraoperative radiotherapy.

Cook Medical

Cook Medical is a pioneer in many medical devices commonly used to perform minimal invasive medical procedures throughout the body. Featured at this meeting is Biodesign an advanced tissue repair technology that gives surgeons a way to achieve lasting results—not with a permanent material, but with the patient's own tissue. Biodesign is completely remodelled by the body, leaving behind vascularised, organised patient tissue, helping to maintain lasting form.



Covidien (UK) Commercial Ltd

Covidien are proud to be associated once again with ABS in 2012 as corporate patrons, and look forward to meeting you in Bournemouth. At Covidien we're passionate about making surgeons, nurses and other medical professionals as effective as they can be. Our innovations from industry leading brands such as Valleylab and Syneture are known worldwide for helping surgical teams meet the clinical and economic challenges of the modern healthcare world.

Cytori GmbH

Celution, Puregraft and Celbrush are medical devices developed and indicated for breast reconstruction surgery using lipomodelling.

DAAX Ltd

DAAX Ltd represents Faxitron Inc (in the UK/Ireland) leaders in pioneering digital mammography. COREVISION is a specialist cost effective device for core biopsy imaging positioned next to your mammo unit. BIOVISION is for core biopsy and surgical specimens; portable for use in theatre, screening or moved between both.

Devicor Medical UK Ltd

MMT is the global market leader in vacuum-assisted breast biopsy and offers physicians and women a wide range of options and diagnostic tools.

FaHRAS Ltd

Family history risk assessment software.

Genomic Health Inc

Genomic Health is a molecular diagnostics company focused on the global development and commercialisation of genomic-based clinical laboratory services that analyse the underlying biology of cancer allowing physicians and patients to make individualised treatment decisions. More than 10,000 physicians in over 60 countries have ordered more than 250,000 Oncotype DX® tests for breast and colon cancer patients.

Hologic UK Ltd

Hologic Inc is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems and surgical products dedicated to serving the healthcare needs of women, with a focus on mammography, breast biopsy and radiation treatment for early-stage breast cancer.

IGEA UK

Electrochemotherapy, a novel technique for the treatment of local skin recurrence.

International Health Technology Ltd

Photo Dynamic Eye for sentinel node biopsy.

Lifecell, A KCI Company

Since 1994, LifeCell Corporation has been a pioneer in the science of regenerative medicine. LifeCell CorporationTissueMatriceshavebeenusedsuccessfully in more than one million grafts and implants to date. The range of surgical applications include hernia repair, breast reconstruction post-mastectomy, breast plastic surgery (breast augmentation revisions) and other reconstructive applications. Since 2008 our next generation soft-tissue repair product, Strattice™ Reconstructive Tissue Matrix, is being used by an increasing number of surgeons worldwide for hernia and abdominal wall repair and breast reconstruction.

Mammary Fold

Breast trainees group.

Mana-Tech Ltd

Hydromark is the ultimate site marker for Neoadjuvant patients. The biodegradable polymer gel swells (absorbs 90% water) to provide outstanding ultrasound visibility that will last a year to cover the whole treatment period.

Medasun Ltd

Post surgical support bras.

Mentor Medical Systems

At Mentor it is our aim to be the trusted leader in aesthetics among consumers & professionals to maintain, enhance and restore self-esteem & quality of life. Mentor is a member of the Johnson & Johnson family of medical companies.

Nago

Breast, body and facial implants, tissue expanders and anti-scar treatment.

Nicola Jane

Experts in post-surgery fashion for over 28 years, helping to restore confidence and femininity after breast cancer.

Novartis Pharmaceuticals UK Ltd

Novartis Oncology has a strong heritage in cancer care. Indeed, over the past 25 years pioneering research has repeatedly resulted in new and innovative products, like the cutting edge, rationally designed, molecularly targeted compounds.

Oxford Shirt Co Ltd

Selection of ladies and men's classic shirts in a variety of fabrics.

QADOS

Sentinel Lymph Node Probes.

Q Medical Technologies Ltd

Q Medical will be presenting the Polytech range of Polyurethane coated implants, available in sizes from 100mls to over 1,000mls. We will also be discussing Surgimend ADM for post mastectomy breast reconstruction.

Roche

Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche in the UK employs nearly 2,000 people in pharmaceuticals and diagnostics. For more information: www.roche.co.uk

Sigmacon (UK) Ltd

With the portfolio of state of the art Medical Aesthetic devices from market leaders such as LUMENIS™ and ELLMAN™ Sigmacon Aesthetics are true market leaders in the provision of new modalities.

Smith & Nephew Advanced Wound ManagementSmith & Nephew Wound Management is world leader in advanced wound care; providing a range of treatments for the management of soft tissue injuries.





Find Out Mor



Managing Post-Operative Lymph Drainage Following Breast Surgery

Innovating Solutions in Advanced Energy Technology

Today's surgical options for breast cancer allow for increasingly conservative treatments.

However, managing post-operative complications, especially those associated with drainage, remains a key concern. While post-operative lymph drainage is standard practice, complications including seroma and lymphedema persist.

In order to meet surgeon's needs, Covidien has introduced a new solution informed by input from surgeons around the world and backed by the demonstrated performance of LigaSure[™] Technology.

Let Us Show You

"Compared to conventional techniques (4.3 days versus 5.7 days). Presented as "Sistema de sellado de vasos (LigaSure™) vs. tecnicas convensionales en cirugia axillar: estuidio prospective randomizado" (Vessel sealing system (LigaSure™) vs. conventional techniques in axillary surgeny: a prospective randomized study), Poster, Congresso de Ginecologia Oncologica y Patalogia Mamaria de la Sego, October 2010.

Southern Scientific Ltd

Suppliers of mammography systems and QA products, as well as gamma probes for sentinel node biopsy.

Sysmex UK Ltd

The Sysmex OSNA (One Step Nucleic Acid Amplification) system has provided intra-operative results for over 20,000 breast cancer patients across Europe which has allowed these patients to undergo 'One Step Surgery' as part of their treatment, sparing them the stress and anxiety of waiting for their test results and for some facilitating immediate breast reconstruction. A podcast detailing one patient's experience is available on our website: www.sysmex-lifescience.com/penny

Teasdale Surgical Ltd

Specialist in surgical retraction and devices to improve surgical access.

Thamert UK

Silicone and fibrefill breastforms, bras and accessories.

Womanzone Distribution Ltd

Womanzone offer an exciting exclusive range of light, soft and satin feel breast forms available on NHS contract.



General Information

Registration Desk

Registration will be open in the Purbeck Foyer at the following times:

Monday 21st May 2012: 07:45 to 19:15 Tuesday 22nd May 2012: 08:30 to 16:45

Lunch and Refreshments

Lunch and refreshments will be served at the times listed in the programme in the Purbeck Hall.

A/V Preview Room

An A/V Preview Room will be available in the Tregonwell Bar for the duration of the meeting. Would any speaker who needs to hand their presentation in please take it to this room on arrival.

Posters

The poster presentations will be displayed in the Purbeck Hall for the duration of the meeting. Please can all poster presenters mark and store their poster tubes in the boxes provided in this room. These will then be stored at registration. Posters should be removed between 13:45 and 14:00 on Tuesday 22nd May and can be stored at registration for the afternoon session if required.

Cloakroom

A cloakroom and luggage store will be available in the Purbeck Bar for the duration of the meeting

Security

In the interests of security, delegates are required to wear their name badges at all times during the meeting.

ABS Annual Dinner

The ABS Annual Dinner will be held at the Bournemouth Pavilion Theatre & Ballroom (Westover Road, Bournemouth BH1 2BU) on Monday 21st May 2012 at 7.30pm for 8pm. There is a pay and display car park at the venue if required. Dress is lounge suits.


CPD

This meeting has been awarded CPD points by the Association of Surgeons of Great Britain and Ireland as follows:

Monday 21st May 2012: 7 points Tuesday 22nd May 2012: 6 points

Photography

A photographer will be taking images of the conference on Monday 21st May for use in future ABS publications. If you do wish to have images of yourself used by the ABS please let Lucy Davies know by e-mail to: lucydavies@absqbi.org.uk



This meeting is supported by educational grants from the Association of Breast Surgery's corporate sponsors:









We make it visible.



















